Skip to main content

Applied Molecular Transport, Inc. (AMTI)

NASDAQ: AMTI · IEX Real-Time Price · USD
16.33
-2.66 (-14.01%)
At close: Nov 26, 2021 1:00 PM
17.34
1.01 (6.18%)
After-hours:Nov 26, 2021 4:07 PM EST
Market Cap628.54M
Revenue (ttm)n/a
Net Income (ttm)-89.17M
Shares Out38.49M
EPS (ttm)-2.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume172,863
Open22.81
Previous Close18.99
Day's Range15.89 - 19.02
52-Week Range20.50 - 78.22
Betan/a
AnalystsStrong Buy
Price Target75.75 (+363.9%)
Earnings DateNov 11, 2021

About AMTI

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I...

IndustryBiotechnology
IPO DateJun 5, 2020
Employees113
Stock ExchangeNASDAQ
Ticker SymbolAMTI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AMTI stock is "Strong Buy." The 12-month stock price forecast is 75.75, which is an increase of 363.87% from the latest price.

Price Target
$75.75
(363.87% upside)
Analyst Consensus: Strong Buy

News

Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021

Management to highlight novel oral biologics technology platform, clinical programs and research activities

1 month ago - GlobeNewsWire

Applied Molecular Transport Announces Upcoming Investor Events in September and October

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will p...

2 months ago - GlobeNewsWire

Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly...

3 months ago - GlobeNewsWire

Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance

3 months ago - GlobeNewsWire

Applied Molecular Transport to Present at Canaccord Genuity's 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D...

3 months ago - GlobeNewsWire

Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECC...

Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology

4 months ago - GlobeNewsWire

Applied Molecular Transport to Present at Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D....

6 months ago - GlobeNewsWire

Applied Molecular Transport Reports First Quarter 2021 Financial Results and Provides Corporate Update

Enrollment ongoing in each of oral AMT-101's four Phase 2 trials

6 months ago - GlobeNewsWire

Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Pur...

SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its prev...

7 months ago - GlobeNewsWire

Applied Molecular Transport Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an under...

7 months ago - GlobeNewsWire

Applied Molecular Transport Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced a...

7 months ago - GlobeNewsWire

Applied Molecular Transport Appoints Earl Douglas as General Counsel

Company continues to strengthen key functions of corporate leadership

8 months ago - GlobeNewsWire

Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing

8 months ago - GlobeNewsWire

3 Biotech Stocks That Have Already Rocketed Higher in 2021

Here's why these highfliers could have more fuel in the tank.

Other symbols:GRTSMRNA
8 months ago - The Motley Fool

Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph....

8 months ago - GlobeNewsWire

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT...

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects

8 months ago - GlobeNewsWire